Great Point Partners LLC Increases Stock Position in OptiNose, Inc. (NASDAQ:OPTN)

Great Point Partners LLC grew its position in shares of OptiNose, Inc. (NASDAQ:OPTN) by 56.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,727,097 shares of the company’s stock after purchasing an additional 4,940,779 shares during the quarter. OptiNose makes up about 2.7% of Great Point Partners LLC’s holdings, making the stock its 17th largest position. Great Point Partners LLC owned 12.14% of OptiNose worth $14,276,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. HighMark Wealth Management LLC acquired a new stake in shares of OptiNose in the 1st quarter valued at about $36,000. XTX Topco Ltd acquired a new stake in shares of OptiNose in the second quarter valued at approximately $88,000. Oracle Investment Management Inc. purchased a new position in shares of OptiNose during the first quarter worth approximately $474,000. Easterly Investment Partners LLC increased its holdings in shares of OptiNose by 10.2% in the 2nd quarter. Easterly Investment Partners LLC now owns 2,246,224 shares of the company’s stock valued at $2,336,000 after acquiring an additional 208,185 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in OptiNose by 2.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,920,309 shares of the company’s stock valued at $3,037,000 after purchasing an additional 81,233 shares during the last quarter. Institutional investors and hedge funds own 85.60% of the company’s stock.

Insider Activity at OptiNose

In other OptiNose news, insider Michael F. Marino III sold 49,408 shares of the company’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $1.14, for a total transaction of $56,325.12. Following the completion of the transaction, the insider now owns 550,464 shares in the company, valued at approximately $627,528.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Michael F. Marino III sold 49,408 shares of the business’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $1.14, for a total transaction of $56,325.12. Following the transaction, the insider now directly owns 550,464 shares in the company, valued at $627,528.96. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Ramy A. Mahmoud sold 111,426 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $1.14, for a total transaction of $127,025.64. Following the completion of the sale, the chief executive officer now owns 1,206,978 shares of the company’s stock, valued at approximately $1,375,954.92. The disclosure for this sale can be found here. Insiders have sold a total of 167,679 shares of company stock worth $191,154 in the last three months. Insiders own 2.70% of the company’s stock.

OptiNose Price Performance

Shares of NASDAQ:OPTN opened at $0.72 on Tuesday. OptiNose, Inc. has a 1-year low of $0.72 and a 1-year high of $2.10. The stock has a market cap of $81.39 million, a P/E ratio of -2.67 and a beta of -0.04. The firm has a fifty day moving average price of $0.97 and a 200 day moving average price of $1.13.

OptiNose (NASDAQ:OPTN) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $20.49 million for the quarter, compared to analysts’ expectations of $20.81 million. Sell-side analysts expect that OptiNose, Inc. will post -0.22 EPS for the current fiscal year.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.